Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

vTv Therapeutics (VTVT) Cash from Investing Activities (2017 - 2023)

vTv Therapeutics (VTVT) has disclosed Cash from Investing Activities for 6 consecutive years, with $4.4 million as the latest value for Q4 2023.

Quarterly Cash from Investing Activities changed N/A to $4.4 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2023, changed N/A year-over-year, with the annual reading at $4.4 million for FY2023, 21071.43% up from the prior year.
Cash from Investing Activities hit $4.4 million in Q4 2023 for vTv Therapeutics, up from -$68000.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of $4.4 million in Q4 2023 to a low of -$68000.0 in Q4 2019.